Allogeneic stem cell transplantation (SCT) is a widely accepted therapeutic option for various hematological neoplasias and an increasing variety of other malignant disorders. New reduced-intensity conditioning regimens, many of them including fludarabine 2-fluoroadenine 9-beta-D-arabinofuranoside (F-Ara), have extended patient selection and clinical entities elegible for SCT 1 and aim to reduce conditioning-related toxicity (reviewed in Ferrara et al 2 ). However, F-Ara-based approaches still show high incidences of acute and chronic graft-versus-host disease (GvHD) as primary causes of treatment-related mortality. 3 In addition, F-Ara had been shown to target not only malignant hematopoetic cells but can also be harmful for endothelial (EC) and dermal as well as alveolar epithelial cells. 4 Next to its induction of apoptosis in these cells, F-Ara also increases the antigenicity of EC towards CD8 þ T c 1-type cytotoxic T lymphocytes (CTL) resulting in additional damage of these cells. 4 This is of pivotal importance, since essentially all transplant-related complications are associated with endothelial dysfunction and damage. 5 On the basis of search for endothelium-protective drugs, defibrotide (DF), a polydeoxynucleotide, turned out to be effective in several vascular disorders, including venoocclusive disease (VOD). 6, 7 In addition, we were able to show in in vitro studies that DF protects EC from F-Arainduced damage, activation and allogenicity. 4 Recently, a derivative of DF, Oligotide, has been developed by Gentium, Sp.A., and its endothelium-protective effects have been shown for traumatic shock, 8 myocardial 9,10 and renal 11, 12 ischemia reperfusion injury, where endothelial damage has most extensively been studied so far. The protective potential of Oligotide against conditioningrelated toxicity prior to SCT is enigmatic and the majority of data available are derived from animal systems. The present study, therefore, aimed to evaluate the efficacy of Oligotide in its protection of F-Ara-mediated damage and (allo)activation of human EC. Owing to the observation that Oligotide can inhibit leukocyte-endothelial adhesion, [13] [14] [15] it was reasonable to investigate its influence on F-Ara-induced transendothelial migration of peripheral blood mononuclear cells (PBMC). In addition, dose comparisons with DF have been performed.
Methods

Cell culture and reagents
The human dermal microvascular endothelial cell line CDC/EU.-HMEC-1 (further referred to as HMEC) was kindly provided by the centers for Disease Control and Prevention (Atlanta, Georgia, USA) and has been established as previously described. 16 HMEC were cultured in MCDB131 medium, supplemented with 15% fetal calf serum (FCS), 1 mg/ml hydrocortisone (Sigma, Deisenhofen, Germany), 10 ng/ml epidermal growth factor (Collaborative Biochemical Products, Bedford, MA, USA) and antibiotics. All cell culture reagents have been purchased by Gibco BRL (Karlsruhe, Germany) unless stated otherwise. F-Ara, the metabolized isoform of the clinically used F-Ara was obtained from Sigma, Deisenhofen, Germany. Oligotide, as similar to DF, was manufactured by Gentium, Sp.A., Como, Italy, as a sodium salt of a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine intestinal DNA under controlled depolymerization conditions. The chain length of Oligotide is distributed in a Gaussian-like fashion with a mean molecular weight of 872 kDa and with a purine/pyrimidine nucleotide molar ratio of 1.070.2.
14 It is nuclease-sensitive.
Apoptosis assays
An established method for detecting apoptosis in human endothelial cells (EC) was performed as previously described 17 using flow cytometry (FACScant and CellQuestt software, Becton Dickinson, Heidelberg, Germany). Endothelial and epithelial cells were either left untreated or incubated with F-Ara in descending concentrations (10 mg/ ml, dose kinetics had been established in Eissner et al /plate EC were seeded in 35 mm Petri dishes (Nunc, Wiesbaden, Germany). These cells were treated as given above and subsequently fixed with methanol/acetone (1:1) for 2 min, washed once in PBS and stained with 4,6-diamidino-2-phenylindole (DAPI) (0.5 mg/ml, Sigma, Deisenhofen, Germany), dissolved in 20% glycerin/PBS. Samples were mounted and subjected to microscopic analysis. Nuclear condensation as revealed by DAPI staining in the absence of trypan blue uptake is considered characteristic of apoptosis as opposed to necrosis. 18 The quantitative analysis included counting the number of apoptotic relative to all identifiable cells from at least 10 microscopic fields, with an average of 70 cells per field. For the sake of the clarity of the manuscript, DAPI stain results are only mentioned in the text.
Cell surface analyses
Cell surface expression of ICAM-1 (Becton Dickinson/ Pharmingen, Heidelberg, Germany) on HMEC was assessed by the indirect immunofluorescence technique and subsequent flow cytometry using the FACScant flow cytometer and the CellQuestt analysis program (Becton Dickinson, Heidelberg, Germany). EC were treated as given and after incubation harvested with trypsin/EDTA (Gibco), washed once in cold PBS/10% FCS and incubated for 1 h on ice with 5 mg/ml of the primary antibody. Cells were washed again and incubated with a goat anti-mouse IgG-FITC-conjugated antibody F(ab) 2 fragment (Dako, Hamburg, Germany) for 45 min on ice. Cells were then washed in PBS/10% FCS and subjected to analysis. Viability of the cells was determined by concurrent PI (0.2 mg/ml, Sigma, Deisenhofen, Germany) staining. Isotype-matched antibodies served as negative controls to detect unspecific fluorescence.
Allostimulation of peripheral blood cells with HMEC
PBMC were derived from heparinized (Novo Nordisk, Mainz, Germany) blood of healthy human volunteers following a standard protocol using Ficoll hypaque (Pharmacia, Freiburg, Germany) density gradient centrifugation. PBMC were selected for CD8 þ T cells using cell isolation kits according to the manufacturer's instructions (MACSt, Miltenyi Biotech, Bergisch-Gladbach, Germany) based on the deletion of non-CD8 þ cells. CD8 þ T cells were then stimulated in a ratio of 1:1 and 2:1 with irradiated (20 Gy) HMEC for 7 days in the presence of interleukin 2 (50 U/ml) and 10% human AB serum (Sigma, Deisenhofen, Germany).
Assay for transendothelial migration
The migration of PBMC through endothelial monolayers was assessed as previously described. 19, 20 Briefly, HMEC were plated to confluence onto Matrigelt-coated polycarbonate filter inserts (Becton Dickinson, Heidelberg, Germany) for 24-well plates with a pore size of 3 mm. To prove that the endothelial cell monolayer was intact, all migration chambers were carefully investigated microscopically. After treatment of HMEC with F-Ara and/or DF or Oligotide, respectively, overnight, PBMC were allowed to migrate through the endothelial layer overnight. Migrated cells were counted by trypan blue exclusion.
Cytotoxicity assay
T-cell-or NK-cell-mediated cytotoxicity was assessed according to a well-established protocol 21 using a 4 h 51 Cr radioisotope assay. As targets, HMEC were either left untreated or incubated with F-Ara (10 mg/ml) in the persence or absence of DF or Oligotide, respectively, overnight. Subsequently, they were labeled with 180 MBq Na 2 51 CrO 4 for 2 h. After three washing steps, target cells were adjusted to 10 4 cells/ml and coincubated with CD8 þ T cells at descending effector to target ratios for another 4 h. Supernatants were transfered to dry scintillation plates and counted in a g-counter (all from Canberra Packard, Darmstadt, Germany). K562 as Natural Killer cellsensitive targets were taken as negative controls. The percentage of specific lysis was calculated as: ((experimental releaseÀspontaneous release)/(maximal releaseÀsponta-neous release)) Â 100. Spontaneous release in all experiments was always below 20%.
Statistical analysis
The significance of differences between experimental values was assessed by means of Student's t-test.
Results
Oligotide dose-dependently inhibits the F-Ara-mediated apoptosis of HMEC HMEC had either been left untreated (HMEC Control) or incubated with F-Ara in the presence or absence of descending concentrations of Oligotide (100-0.1 mg/ml) and assessed for programmed cell death after 48 h using flow cytometric analyses of the SSC image as described in methods. Figure 1a shows that Oligotide alone as a control did not influence endothelial cell viability (upper right contour plot). F-Ara as described 4 induced apoptosis in HMEC (48% apoptotic cells, contour plot, second row), whereas Oligotide showed a dose-dependent protection of F-Ara-induced cell death in concentrations as low as 1 mg/ml. In order to exclude unspecific artificial extracellular interaction of F-Ara and Oligotide in vitro, HMEC were pretreated with Oligotide for 1 h and subsequently, after three washing steps, incubated with F-Ara for another 48 h and vice versa. As it had been shown for DF, 4 pretreatment of HMEC with Oligotide for 1 h was sufficient to protect cells from F-Ara-induced apoptosis. Similarly, pretreatment of HMEC with F-Ara for 1 h and subsequent incubation with Oligotide did not lead to endothelial programmed cell death (data not shown). Cumulative analysis of three independent experiments revealed the statistical significance of our observation (Figure 1b) . HMEC apoptosis under the influence of F-Ara normalized to apoptosis of untreated control HMEC could fully be blocked by concentrations of Oligotide as low as 1 mg/ml (P ¼ 0.03 for 100 mg/ml Oligotide). To confirm results obtained with flow cytometry, an alternative apoptosis assay was performed using a DNA dye (DAPI) staining and subsequent fluorescence microscopic analysis as described in the Methods section. Similar to the SSC data, Oligotide (100 mg/ml) fully blocked F-Ara-induced apoptosis (11.9% (70.6) apoptotic HMEC as compared to F-Ara alone (37.8% (75.5) apoptotic cells) (Po0.001 for F-Ara vs F-Ara þ Oligotide), Control HMEC 9.7% (71.5), data not shown).
Oligotide protects HMEC against the F-Ara-mediated upregulation of intercellular adhesion molecule 1 (ICAM-1) and transendothelial migration of peripheral blood cells Based on previous observations that pretransplant conditioning not only damages but also leads to proinflammatory activation of EC in terms of adhesion molecule induction 22 and, as a final inflammatory consequence, transendothelial migration, 23 we next investigated the Oligotide attenuates the F-Ara-induced antigenicity of EC towards allogeneic CD8 þ cytotoxic T lymphocytes Previous studies on the increased allocytotoxic responses of CD8 þ CTL against F-Ara-treated HMEC and the protective effect of DF 4 prompted us to examine whether Oligotide would also be active in this immunomodulatory setting. PBMC from healthy donors were selected for CD8 þ T cells (non-CD8 depletion) using magnetic bead separation with MACSt bead kits. Purity of the preparations was X85% in all experiments with a complete absence of CD4 and natural killer (NK) cells, respectively (below 2%). CD8 þ effectors were stimulated with irradiated (20 Gy) HMEC in the presence of 50 U/ml interleukin 2 (IL-2) for 7 days and subsequently subjected to a standard 51 Cr release assay (for details see Methods). At day À1, fresh HMEC as targets were either left unstimulated or incubated with F-Ara (10 mg/ml) in the presence or absence of Oligotide (100 mg/ml) for 24 h. K562 cells as classical NK cell targets served as controls. As shown in Figure 3 , lysis of F-Ara-treated HMEC by CD8 þ CTL was significantly higher than that of control HMEC (99% specific lysis of F-Ara-treated HMEC vs 84% of Control HMEC at an effector/target ratio of 100:1 (E/T 100)). Interestingly, pretreatment of target HMEC Cr release assay with untreated (Control HMEC, circles) and F-Ara (10 mg/ml, squares)-and F-Ara þ Oligotide (100 mg/ml, rhombi)-treated HMEC (24 h incubation) as target cells. Results are given as % specific lysis as described in methods. E/T ratio: effector/target ratio. This is a representative out of three independent experiments. with F-Ara and Oligotide downregulated specific lysis even below control levels (72% specific lysis at E/T 100), specific lysis of K562 cells was below 9% at E/T 100, excluding that CTL activity was due to an unrestricted lymphokineactivated killing, or alternatively an NK cell activation (data not shown). These data suggest that Oligotide also protects EC against the lysis of allogeneic effector lymphocytes.
Discussion
In the present study, we have shown that the polydeoxyribonucleotide Oligotide is a potent inhibitor of F-Aramediated damage and activation of human EC, as could be observed previously for its derivative DF. 4 Additional dose kinetics revealed that Oligotide, at least in our experimental system, is 10-fold more effective than DF. These potential anti-inflammatory properties of Oligotide, including the inhibition of F-Ara-induced transendothelial migration, render this drug a good candidate for the protection of EC.
The precise mechanism how F-Ara induces apoptosis in HMEC remains to be elucidated, and so does the mechanism of protection by DF and Oligotide. However, it is likely that fludarabine -as a purine analogueintegrates into the DNA and thus inhibits chain elongation 24 and causes mutations that ultimately lead to gene deletion, as reported previously. 25 It has also been suggested that fludarabine can cooperate with cytochrome c and apoptosis protein-activating factor-1 (APAF-1) in triggering the apoptotic caspase pathway. 26 Probably, DF and/or Oligotide interfere with one of these mechanisms. Of note, Oligotide, exactly like DF, 4 was not protective against radiation-and endotoxin plus radiation-induced endothelial cell damage, 27, 28 suggesting its effect to be specific for FAra-mediated cellular changes (data not shown).
It will be interesting to see whether Oligotide is comparably protective against conditioning-related toxicity in cell types other than EC, such as it has been shown for DF in F-Ara-sensitive alveolar epithelial cells and keratinocytes. 4 Even more importantly and as a prerequisite for a potential clinical use of Oligotide, it has to be clarified if Oligotide might interfere with the antileukemic and antihematopoietic properties of F-Ara. Based on the fact that DF does not attenuate these desirable effects of F-Ara, 4 one would predict a similar outcome for Oligotide.
The observation that Oligotide also modulates the FAra-induced alloresponse of CD8 þ CTL against EC warrants further investigation on the mechanism, for example, MHC restriction and the role of costimulatory molecules that might be affected by this drug.
Since DF is a well-tolerated drug successfully used for the treatment of veno-occlusive disease as one major hepatic complication post-SCT, 6, 7, 29, 30 and since we have suggested to also use it in pretransplant conditioning, 4 one could hypothesize similar therapeutic and/or prophylactic approaches for Oligotide. Ongoing clinical phase I/II trials will help to answer this question. In support of this concept, the preemptive use of DF has very recently been shown to be protective against the development of VOD. 31 
